Acute Kidney InjuryKidney and urinary
What this study is
This is a pilot observational cohort study to understand whether advanced monitoring techniques can be applied during continuous kidney replacement therapy (CKRT), which is the most common form of dialytic therapy provided in critically ill patients.
Study details
- Official title
- Feasibility of Intradialytic Hematocrit and Oxygen Saturation Monitoring During Continuous Kidney Replacement Therapy
- Sponsor
- University of Pennsylvania
- Conditions
- Acute Kidney Injury · End Stage Chronic Renal Failure · Dialysis
- Enrolling
- 30 people
- Starts
- 2026-03-17
- Est. completion
- 2028-03
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Patients who have been admitted to the Medical ICU or Cardiothoracic ICU at the Hospital of the University of Pennsylvania (HUP).
- Patients who have been prescribed continuous venovenous hemodialysis (CVVHD) or Continuous Veno-Venous Hemofiltration (CVVH), the predominant modalities of continuous kidney replacement therapy (CKRT) at HUP.
- Patients who have central venous catheters placed in either the left or right internal jugular veins.
You can't join if
- Patients who are prescribed other forms of CKRT, namely continuous venovenous hemofiltration (CVVH), slow continuous ultrafiltration (SCUF), or prolonged intermittent kidney replacement therapy (PIKRT).
- Patients who have femoral vein dialysis catheters placed.
- Patients who cannot provide consent or have a legal proxy to provide consent.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openUniversity of Pennsylvania
Philadelphia, Pennsylvania, United States
Study team
Sponsor
University of Pennsylvania
Study ID 855545
Have questions? The record lists no central contact. Use Consider me and the site team can reach you, or find them through ClinicalTrials.gov ↗.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.